Cargando…

Effect of Daratumumab combined with Chemotherapy on Immune Function in Patients with Relapsed/Refractory Multiple Myeloma and Observation of its Clinical Efficacy

OBJECTIVE: To evaluate the clinical efficacy and immune function of Daratumumab combined with chemotherapy in patients with relapsed/refractory multiple myeloma (RRMM). METHODS: Eighty patients with RRMM treated in Xingtai People’s Hospital from January, 2020 to December, 2021 were randomly divided...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ye-hua, Xu, Feng, Xu, Chang-qing, Zhang, Zi-tan, Jiao, Zong-jiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Professional Medical Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843002/
https://www.ncbi.nlm.nih.gov/pubmed/36694744
http://dx.doi.org/10.12669/pjms.39.1.6667
_version_ 1784870282698162176
author Zhang, Ye-hua
Xu, Feng
Xu, Chang-qing
Zhang, Zi-tan
Jiao, Zong-jiu
author_facet Zhang, Ye-hua
Xu, Feng
Xu, Chang-qing
Zhang, Zi-tan
Jiao, Zong-jiu
author_sort Zhang, Ye-hua
collection PubMed
description OBJECTIVE: To evaluate the clinical efficacy and immune function of Daratumumab combined with chemotherapy in patients with relapsed/refractory multiple myeloma (RRMM). METHODS: Eighty patients with RRMM treated in Xingtai People’s Hospital from January, 2020 to December, 2021 were randomly divided into two groups. Patients in the study group were treated with Daratumumab combined with PAD regimen, while patients in the control group were provided with PAD regimen alone. Further comparison was performed on the therapeutic effects, adverse drug reactions, the levels of T lymphocyte subsets CD3(+), CD4(+), CD8(+) and CD4(+)/CD8(+), the positive expression rate of CD38 and the expression level of Notch-1 on the membrane of plasma cells between the two groups. RESULTS: The overall response rate in the study group (67.50%) was significantly better than that in the control group (45.00%). There was no significant difference in the incidence of adverse reactions between the two groups. After treatment, the reviewed levels of CD3(+), CD4(+) and CD4(+)/CD8(+) were obviously higher in the study group than those in the control group, while the positive expression rate of CD38 and the expression level of Notch one on the membrane of plasma cells were both lower than those in the control group (p<0.05). CONCLUSION: Daratumumab combined with a PAD regimen is a safe and effective approach that has a definite curative effect on patients with RRMM, which can improve immune function significantly and result in no significant increase in adverse reactions.
format Online
Article
Text
id pubmed-9843002
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Professional Medical Publications
record_format MEDLINE/PubMed
spelling pubmed-98430022023-01-23 Effect of Daratumumab combined with Chemotherapy on Immune Function in Patients with Relapsed/Refractory Multiple Myeloma and Observation of its Clinical Efficacy Zhang, Ye-hua Xu, Feng Xu, Chang-qing Zhang, Zi-tan Jiao, Zong-jiu Pak J Med Sci Original Article OBJECTIVE: To evaluate the clinical efficacy and immune function of Daratumumab combined with chemotherapy in patients with relapsed/refractory multiple myeloma (RRMM). METHODS: Eighty patients with RRMM treated in Xingtai People’s Hospital from January, 2020 to December, 2021 were randomly divided into two groups. Patients in the study group were treated with Daratumumab combined with PAD regimen, while patients in the control group were provided with PAD regimen alone. Further comparison was performed on the therapeutic effects, adverse drug reactions, the levels of T lymphocyte subsets CD3(+), CD4(+), CD8(+) and CD4(+)/CD8(+), the positive expression rate of CD38 and the expression level of Notch-1 on the membrane of plasma cells between the two groups. RESULTS: The overall response rate in the study group (67.50%) was significantly better than that in the control group (45.00%). There was no significant difference in the incidence of adverse reactions between the two groups. After treatment, the reviewed levels of CD3(+), CD4(+) and CD4(+)/CD8(+) were obviously higher in the study group than those in the control group, while the positive expression rate of CD38 and the expression level of Notch one on the membrane of plasma cells were both lower than those in the control group (p<0.05). CONCLUSION: Daratumumab combined with a PAD regimen is a safe and effective approach that has a definite curative effect on patients with RRMM, which can improve immune function significantly and result in no significant increase in adverse reactions. Professional Medical Publications 2023 /pmc/articles/PMC9843002/ /pubmed/36694744 http://dx.doi.org/10.12669/pjms.39.1.6667 Text en Copyright: © Pakistan Journal of Medical Sciences https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0 (https://creativecommons.org/licenses/by/3.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Zhang, Ye-hua
Xu, Feng
Xu, Chang-qing
Zhang, Zi-tan
Jiao, Zong-jiu
Effect of Daratumumab combined with Chemotherapy on Immune Function in Patients with Relapsed/Refractory Multiple Myeloma and Observation of its Clinical Efficacy
title Effect of Daratumumab combined with Chemotherapy on Immune Function in Patients with Relapsed/Refractory Multiple Myeloma and Observation of its Clinical Efficacy
title_full Effect of Daratumumab combined with Chemotherapy on Immune Function in Patients with Relapsed/Refractory Multiple Myeloma and Observation of its Clinical Efficacy
title_fullStr Effect of Daratumumab combined with Chemotherapy on Immune Function in Patients with Relapsed/Refractory Multiple Myeloma and Observation of its Clinical Efficacy
title_full_unstemmed Effect of Daratumumab combined with Chemotherapy on Immune Function in Patients with Relapsed/Refractory Multiple Myeloma and Observation of its Clinical Efficacy
title_short Effect of Daratumumab combined with Chemotherapy on Immune Function in Patients with Relapsed/Refractory Multiple Myeloma and Observation of its Clinical Efficacy
title_sort effect of daratumumab combined with chemotherapy on immune function in patients with relapsed/refractory multiple myeloma and observation of its clinical efficacy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843002/
https://www.ncbi.nlm.nih.gov/pubmed/36694744
http://dx.doi.org/10.12669/pjms.39.1.6667
work_keys_str_mv AT zhangyehua effectofdaratumumabcombinedwithchemotherapyonimmunefunctioninpatientswithrelapsedrefractorymultiplemyelomaandobservationofitsclinicalefficacy
AT xufeng effectofdaratumumabcombinedwithchemotherapyonimmunefunctioninpatientswithrelapsedrefractorymultiplemyelomaandobservationofitsclinicalefficacy
AT xuchangqing effectofdaratumumabcombinedwithchemotherapyonimmunefunctioninpatientswithrelapsedrefractorymultiplemyelomaandobservationofitsclinicalefficacy
AT zhangzitan effectofdaratumumabcombinedwithchemotherapyonimmunefunctioninpatientswithrelapsedrefractorymultiplemyelomaandobservationofitsclinicalefficacy
AT jiaozongjiu effectofdaratumumabcombinedwithchemotherapyonimmunefunctioninpatientswithrelapsedrefractorymultiplemyelomaandobservationofitsclinicalefficacy